Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments
Tumori. 2024 Feb 19:3008916241231687. doi: 10.1177/03008916241231687. Online ahead of print.ABSTRACTCutaneous melanoma represents the fifth tumor in terms of incidence in young adults, with a major involvement of males than females. Despite the significant changes in available effective treatments for cutaneous melanoma, there is still a proportion of patients that do not benefit long-term disease control with immune checkpoint inhibitors and/or BRAF/MEK inhibitors, and eventually develop progressive disease. In addition to the emerging biomarkers under investigation to understand resistance to treatments, recent studies r...
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Ida Taglialatela Alice Indini Giulia Santanelli Giorgia Di Liberti Lorenza Di Guardo Filippo De Braud Michele Del Vecchio Source Type: research
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
CONCLUSION: Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.PMID:38372045 | DOI:10.1177/03008916241229287 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Luigi Cerbone Sara Delfanti Stefania Crivellari Antonina Maria De Angelis Laura Mazzeo Claudia Proto Mario Occhipinti Giuseppe Lo Russo Chiara Dellepiane Federica Biello Irene Alabiso Francesco Verderame Roberta Gauna Irene De Simone Federica Cuppone Sand Source Type: research
How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved checkpoint immune inhibitors?
CONCLUSIONS: In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.PMID:38372036 | DOI:10.1177/03008916241229649 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Emanuele Crocetti Alessandra Ravaioli Fabio Falcini Rosa Vattiato Silvia Mancini Flavia Baldacchini Federica Zamagni Benedetta Vitali Chiara Balducci Lauro Bucchi Orietta Giuliani Source Type: research
Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments
Tumori. 2024 Feb 19:3008916241231687. doi: 10.1177/03008916241231687. Online ahead of print.ABSTRACTCutaneous melanoma represents the fifth tumor in terms of incidence in young adults, with a major involvement of males than females. Despite the significant changes in available effective treatments for cutaneous melanoma, there is still a proportion of patients that do not benefit long-term disease control with immune checkpoint inhibitors and/or BRAF/MEK inhibitors, and eventually develop progressive disease. In addition to the emerging biomarkers under investigation to understand resistance to treatments, recent studies r...
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Ida Taglialatela Alice Indini Giulia Santanelli Giorgia Di Liberti Lorenza Di Guardo Filippo De Braud Michele Del Vecchio Source Type: research
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
CONCLUSION: Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.PMID:38372045 | DOI:10.1177/03008916241229287 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Luigi Cerbone Sara Delfanti Stefania Crivellari Antonina Maria De Angelis Laura Mazzeo Claudia Proto Mario Occhipinti Giuseppe Lo Russo Chiara Dellepiane Federica Biello Irene Alabiso Francesco Verderame Roberta Gauna Irene De Simone Federica Cuppone Sand Source Type: research
How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved checkpoint immune inhibitors?
CONCLUSIONS: In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.PMID:38372036 | DOI:10.1177/03008916241229649 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Emanuele Crocetti Alessandra Ravaioli Fabio Falcini Rosa Vattiato Silvia Mancini Flavia Baldacchini Federica Zamagni Benedetta Vitali Chiara Balducci Lauro Bucchi Orietta Giuliani Source Type: research
Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments
Tumori. 2024 Feb 19:3008916241231687. doi: 10.1177/03008916241231687. Online ahead of print.ABSTRACTCutaneous melanoma represents the fifth tumor in terms of incidence in young adults, with a major involvement of males than females. Despite the significant changes in available effective treatments for cutaneous melanoma, there is still a proportion of patients that do not benefit long-term disease control with immune checkpoint inhibitors and/or BRAF/MEK inhibitors, and eventually develop progressive disease. In addition to the emerging biomarkers under investigation to understand resistance to treatments, recent studies r...
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Ida Taglialatela Alice Indini Giulia Santanelli Giorgia Di Liberti Lorenza Di Guardo Filippo De Braud Michele Del Vecchio Source Type: research
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
CONCLUSION: Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.PMID:38372045 | DOI:10.1177/03008916241229287 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Luigi Cerbone Sara Delfanti Stefania Crivellari Antonina Maria De Angelis Laura Mazzeo Claudia Proto Mario Occhipinti Giuseppe Lo Russo Chiara Dellepiane Federica Biello Irene Alabiso Francesco Verderame Roberta Gauna Irene De Simone Federica Cuppone Sand Source Type: research
How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved checkpoint immune inhibitors?
CONCLUSIONS: In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.PMID:38372036 | DOI:10.1177/03008916241229649 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Emanuele Crocetti Alessandra Ravaioli Fabio Falcini Rosa Vattiato Silvia Mancini Flavia Baldacchini Federica Zamagni Benedetta Vitali Chiara Balducci Lauro Bucchi Orietta Giuliani Source Type: research
Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments
Tumori. 2024 Feb 19:3008916241231687. doi: 10.1177/03008916241231687. Online ahead of print.ABSTRACTCutaneous melanoma represents the fifth tumor in terms of incidence in young adults, with a major involvement of males than females. Despite the significant changes in available effective treatments for cutaneous melanoma, there is still a proportion of patients that do not benefit long-term disease control with immune checkpoint inhibitors and/or BRAF/MEK inhibitors, and eventually develop progressive disease. In addition to the emerging biomarkers under investigation to understand resistance to treatments, recent studies r...
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Ida Taglialatela Alice Indini Giulia Santanelli Giorgia Di Liberti Lorenza Di Guardo Filippo De Braud Michele Del Vecchio Source Type: research
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
CONCLUSION: Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.PMID:38372045 | DOI:10.1177/03008916241229287 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Luigi Cerbone Sara Delfanti Stefania Crivellari Antonina Maria De Angelis Laura Mazzeo Claudia Proto Mario Occhipinti Giuseppe Lo Russo Chiara Dellepiane Federica Biello Irene Alabiso Francesco Verderame Roberta Gauna Irene De Simone Federica Cuppone Sand Source Type: research
How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved checkpoint immune inhibitors?
CONCLUSIONS: In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.PMID:38372036 | DOI:10.1177/03008916241229649 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Emanuele Crocetti Alessandra Ravaioli Fabio Falcini Rosa Vattiato Silvia Mancini Flavia Baldacchini Federica Zamagni Benedetta Vitali Chiara Balducci Lauro Bucchi Orietta Giuliani Source Type: research
Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments
Tumori. 2024 Feb 19:3008916241231687. doi: 10.1177/03008916241231687. Online ahead of print.ABSTRACTCutaneous melanoma represents the fifth tumor in terms of incidence in young adults, with a major involvement of males than females. Despite the significant changes in available effective treatments for cutaneous melanoma, there is still a proportion of patients that do not benefit long-term disease control with immune checkpoint inhibitors and/or BRAF/MEK inhibitors, and eventually develop progressive disease. In addition to the emerging biomarkers under investigation to understand resistance to treatments, recent studies r...
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Ida Taglialatela Alice Indini Giulia Santanelli Giorgia Di Liberti Lorenza Di Guardo Filippo De Braud Michele Del Vecchio Source Type: research
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
CONCLUSION: Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.PMID:38372045 | DOI:10.1177/03008916241229287 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Luigi Cerbone Sara Delfanti Stefania Crivellari Antonina Maria De Angelis Laura Mazzeo Claudia Proto Mario Occhipinti Giuseppe Lo Russo Chiara Dellepiane Federica Biello Irene Alabiso Francesco Verderame Roberta Gauna Irene De Simone Federica Cuppone Sand Source Type: research
How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved checkpoint immune inhibitors?
CONCLUSIONS: In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.PMID:38372036 | DOI:10.1177/03008916241229649 (Source: Tumori)
Source: Tumori - February 19, 2024 Category: Cancer & Oncology Authors: Emanuele Crocetti Alessandra Ravaioli Fabio Falcini Rosa Vattiato Silvia Mancini Flavia Baldacchini Federica Zamagni Benedetta Vitali Chiara Balducci Lauro Bucchi Orietta Giuliani Source Type: research
